Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Staccato Apomorphine (AZ-009) for Parkinson's disease patients experiencing OFF episodes has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Staccato Apomorphine (AZ-009) (apomorphine)

Snippet

Sponsor: Alexza Pharmaceuticals, Inc. | Conditions: Parkinson Disease | Phase 2 | Status: TERMINATED